From Tech Transfer to Commercial Scale Viral Manufacturing in 8 months - a CDMO Case Study

Event Overview

The growing and diverse viral manufacturing landscape calls for dedicated solutions supporting rapid tech transfer and scale-up while offering cost-effective production at scale. Achieving these goals using traditional stirred-tank bioreactors presents significant challenges, due to inherent design space limitations. In this context, advances in integrated and automated manufacturing solutions may offer increased flexibility, agility and productivity, which can help manufacturers overcome these challenges.

This webinar will focus on the advantages of structured fixed-bed bioreactor technology and integrated manufacturing approaches. A case study by European CDMO Exothera will be presented, demonstrating tech transfer of a suspension-based adenoviral production process to fixed-bed bioreactors, with 2-fold increase in productivity and scale-up to commercial scale in just 8 months.

Key Learning Objectives

By attending this webinar, the viewer will:

Understand how innovative, scalable-by-design fixed-bed technology addresses limitations associated with stirred-tank bioreactors.
Learn about the advantages of biomass immobilization, supporting high-density cell growth and cost-effective production of advanced therapies and vaccines.
Discover a CDMO tech transfer case study demonstrating optimization of viral productivity and complete manufacturing scale-up within 8 months.

Who Should Attend

Developers and CDMOs looking to scale-up production of vaccines, gene therapies and other advanced therapies
Executives seeking to fast-track translation of their programs to commercial manufacturing
Process development scientists looking to learn about innovative technologies supporting rapid tech transfer and reproducible scale-up

Featured Speakers

Thomas Robert

PhD

Univercells Technologies

Thomas Robert, PhD, currently serves as Product Manager for the NevoLine™ upstream platform at Univercells Technologies. A biologist by training, he earned his PhD in medical sciences, focusing on stem-cell derived therapies for type 1 diabetes. Before taking on his current role, he worked as a Field Application Scientist for Terumo BCT. Thomas has extensive knowledge of the cell and gene therapy field as well as expertise in upstream process development, which he applies to drive the development and commercialization of best-in-class biomanufacturing solutions at Univercells Technologies.

Speaker’s Email: t.robert@univercellstech.com
Speaker’s LinkedIn: https://www.linkedin.com/in/thomas-robert-cell-gene/

Hanna P. Lesch

PhD

Exothera

Hanna P. Lesch, PhD, is a Chief Technology Officer at Exothera, Belgium. Her main responsibilities are technology development and innovation in bioproduction platforms. Her PhD is in Molecular Medicine. Over the years, Hanna has held several Director positions, leading research and development at biotech companies. Her research interest has focused on gene therapy and translational development, including early-stage analytics and the development of scalable, robust manufacturing processes operating under current regulatory guidelines. Hanna has several patents related to vector manufacturing.

Speaker’s Email: h.lesch@exothera.world
Speaker’s LinkedIn:
https://www.linkedin.com/in/hanna-p-lesch-77ba9412/

For any technical questions please contact Nicole Valle: nvalle@mjhevents.com.

Complete this form to enter the webcast. (* indicates required field)

From Tech Transfer to Commercial Scale Viral Manufacturing in 8 months - a CDMO Case Study

Thu, Jun 1, 2023 11:00 AM EDT{LOCAL_TZ}

Complete this form to enter the webcast.
(* indicates required field)